Cadence spikes 12.2% AH on rumored favorable court decision in Exela case

Cadence Pharmaceuticals (CADX) shares rocket another 12.2% AH, adding to gains of 4.6% into the close, following word that a court has issued a favorable decision regarding blocking generic maker Exela Pharmaceuticals until 2021.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs